Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing new therapies in oncology and obesity, aiming to address serious illnesses through innovative scientific approaches to well-understood biological pathways. The company's business model is centered on the successful development, regulatory approval, and commercialization of its drug candidates, as it has not yet generated any revenue from product sales ¹. The primary customer segments are patients with cancer and obesity, and the company generates revenue through licensing agreements and potential future product sales.

The company's pipeline includes CRB-701 and CRB-913. CRB-701 (SYS6002) is a next-generation antibody-drug conjugate (ADC) designed to target Nectin-4 expression on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE). Corbus obtained an exclusive license for CRB-701 from CSPC Megalith Biopharmaceutical Co. Ltd. in February 2023 ² for development and commercialization in the U.S., Canada, the European Union (including the European Free Trade Area), the U.K., and Australia. The company is currently conducting a Phase 1/2 study in the U.S. and Europe, with the dose expansion phase ongoing, and began dosing participants in a PD-1 combination arm with Keytruda® (pembrolizumab) in June 2025. CRB-701 has received fast track designation from the FDA for relapsed or refractory metastatic cervical cancer in December 2024 and for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) in September 2025. CSPC is also investigating CRB-701 in a Phase 3 clinical trial for cervical cancer in China.

CRB-913 is a highly peripherally restricted oral small molecule CB1 receptor inverse agonist intended for the treatment of obesity. This drug is designed to improve safety and tolerability by shifting drug exposure from the brain to the periphery, aiming to reduce gastrointestinal adverse events seen with GLP-1 class drugs. The company initiated a single ascending dose (SAD) and multiple ascending dose (MAD) Phase 1a study in Q1 2025, completing it on December 11, 2025.

The company's pipeline formerly included CRB-601, an anti-αvβ8 integrin monoclonal antibody for solid tumors, which has completed a Phase 1 dose escalation study. However, the program has been deprioritized, and no additional patients are planned for enrollment.

For the fiscal year ended December 31, 2025, Corbus Pharmaceuticals Holdings, Inc. reported a net loss of $78.5 million ³, compared to a net loss of $40.2 million ⁴ for the year ended December 31, 2024. Total operating expenses for 2025 were $85.310 million ⁵, an increase from $48.721 million ⁶ in 2024. Research and development expenses increased by $37.9 million ⁷ to $70.1 million ⁸ in 2025 from $32.2 million ⁹ in 2024. General and administrative expenses decreased by $1.3 million ¹⁰ to $15.2 million ¹¹ in 2025 from $16.5 million ¹² in 2024. The company had cash, cash equivalents, and investments of $163.3 million ¹³ at December 31, 2025. Total current assets were $166.954 million ¹⁴ and total current liabilities were $20.692 million ¹⁵, resulting in working capital of $146.262 million ¹⁶. The company had no total debt at December 31, 2025, as the loan from K2 HealthVentures LLC was repaid in full on August 1, 2024.

Year-over-year, research and development expenses saw a significant increase of 118% ¹⁷. Program-specific costs for CRB-701 increased by $20.8 million ¹⁸, or 162% ¹⁹, due to higher clinical and drug supply-related costs as the Phase 1/2 clinical trial expanded. CRB-913 costs increased by $6.2 million ²⁰, or 86% ²¹, driven by the SAD/MAD portion of the Phase 1a clinical study and the start of Phase 1b enrollment. CRB-601 costs increased by $7.4 million ²², or 155% ²³, due to higher clinical and drug supply costs for its Phase 1 dose escalation study. Personnel-related costs within R&D increased by $3.5 million ²⁴, or 65% ²⁵, primarily due to an increase in headcount. General and administrative expenses decreased by 8% ²⁶, mainly due to a $0.7 million ²⁷ decrease in legal expenses and a $0.4 million ²⁸ decrease in facility expense. Other income, net, decreased by $2.830 million ²⁹ to $1.243 million ³⁰ in 2025 from $4.073 million ³¹ in 2024, primarily due to a reduction in employee retention tax credits.

Significant operational developments during the period include the ongoing dose expansion phase of the CRB-701 Phase 1/2 Western study and the initiation of the PD-1 combination arm with Keytruda® in June 2025. The company also announced data from its Phase 1/2 Western study for CRB-701 at ESMO25 on October 18, 2025, with efficacy data presented for HNSCC, cervical cancer, and mUC patients. For CRB-913, the SAD/MAD Phase 1a study was completed on December 11, 2025, demonstrating a mean 2.9% placebo-adjusted weight loss ³² by Day 14 in the obese MAD cohort (150 mg QD), and a Phase 1b dose-range finding study (CANYON-1) was initiated in December 2025. The CRB-601 program was deprioritized in November 2025 after completing a Phase 1 dose escalation study.

Management expects to meet with the FDA in Q1 2026 to review and discuss the clinical data and registrational study protocols for HNSCC and cervical tumors for CRB-701. The dose expansion phase of the Phase 1/2 Western study for CRB-701 is ongoing. For CRB-913, the Phase 1b dose-range finding study (CANYON-1), which will follow 240 U.S. subjects randomized into 4 arms (placebo, 20 mg, 40 mg, and 60 mg) over a 12-week treatment period followed by a 4-week safety follow-up, is expected to be completed in summer 2026.

The company expects its research and development expenses to increase in the future in connection with the continuation of its CRB-701 and CRB-913 clinical trials. General and administrative expenses are also anticipated to increase to support increased and progressed research and development activities and to operate as a public company.

Based on current operating plans and assumptions regarding clinical timelines and other planned expenditures, the company expects its cash, cash equivalents, and investments of $163.3 million ¹³ at December 31, 2025, will be sufficient to meet its operating and capital requirements through at least twelve months from the issuance of these consolidated financial statements. The company will need to raise significant additional capital to continue to fund operations, including pre-clinical and clinical costs for its product candidates. Potential sources of additional capital include public or private equity, debt financings, government grants, and strategic collaborations. The sale of equity and convertible debt securities may result in dilution to existing stockholders.

The company's ability to obtain data or regulatory support from its China-based licensing partner, CSPC, may be limited or adversely affected by changes in U.S.-China trade policies, including the proposed BIOSECURE bill, and other economic and geopolitical factors. Disruptions to the global economy and supply chains due to geopolitical events may continue to impede global supply chains, leading to longer lead times and increased critical component costs and freight expenses. Inflation can also adversely affect the company by increasing the costs of clinical trials, research and development, and administrative expenses, potentially causing the company to use cash and other liquid assets faster than forecasted.

The company faces several material risks, including a history of operating losses and the expectation of continued substantial losses for the foreseeable future, with an accumulated deficit of $555.4 million ³³ as of December 31, 2025. There is significant uncertainty regarding the ability to obtain regulatory approval for drug candidates, as drug development is a lengthy, expensive, and uncertain process. The company is entirely dependent on third parties for manufacturing its drug candidates, and any failure by these contract manufacturers to obtain regulatory approval, provide sufficient quantities, or meet quality standards could halt or delay commercialization. Reliance on third-party CROs for clinical trials also poses a risk, as their failure to carry out contractual duties or meet deadlines could substantially harm the business. Geopolitical conditions, particularly U.S.-China trade relations and the proposed BIOSECURE bill, could adversely impact operations and the ability to obtain data or regulatory support from its China-based licensing partner. Adverse global economic conditions, including inflation, could increase costs and accelerate cash burn, necessitating additional capital raises sooner than expected. The company's intellectual property protection is difficult and costly to maintain, and product candidates may infringe on the rights of others, leading to costly litigation or delays. Furthermore, the company's ability to use its net operating loss carryforwards and other tax attributes may be limited by "ownership change" provisions under Section 382 of the Internal Revenue Code.

Management emphasizes its commitment to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways, focusing on promising new therapies in oncology and obesity. The company expects to continue incurring significant losses for the foreseeable future as it advances its research and development efforts, particularly with the ongoing CRB-701 and CRB-913 clinical trials. Management anticipates that its cash, cash equivalents, and investments of $163.3 million ¹³ as of December 31, 2025, will be sufficient to meet operating and capital requirements for at least twelve months from the issuance of the consolidated financial statements. Strategic priorities include advancing CRB-701, with an expected meeting with the FDA in Q1 2026 to discuss clinical data and registrational study protocols for HNSCC and cervical tumors, and progressing CRB-913 through its Phase 1b dose-range finding study (CANYON-1), with completion anticipated in summer 2026. The company also plans to seek additional capital through various financing methods to support its ongoing and future operations.